OncoCyte Corporation
US ˙ NasdaqCM ˙ US68235C2061
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityOCX / OncoCyte Corporation
InstitutionNorthern Trust Corp
Latest Disclosed Ownership49,090 shares
Latest Disclosed Value $ 161,015
Northern Trust Corp reports 0.47% increase in ownership of OCX / OncoCyte Corporation

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 49,090 shares of OncoCyte Corporation (US:OCX) valued at $161,015 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 48,858 shares of OncoCyte Corporation. This represents a change in shares of 0.47% during the quarter. The current value of the position is $157,088 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 49,090 232 0.47 161 -56.01 0.0000
2026-02-17 2025-12-31 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 48,858 15,968 48.55 366 235.78 0.0000
2025-11-14 2025-09-30 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 32,890 0 0.00 109 10.10 0.0000
2025-08-13 2025-06-30 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 32,890 3,821 13.14 99 12.50 0.0000
2025-05-13 2025-03-31 13F ONCOCYTE COM NEW 68235C206 29,069 11,736 67.71 89 114.63 0.0000
2025-02-14 2024-12-31 13F ONCOCYTE COM NEW 68235C206 17,333 -13 -0.07 41 -16.33 0.0000
2024-11-13 2024-09-30 13F ONCOCYTE COM 68235C206 17,346 0 0.00 49 -3.92 0.0000
2024-08-14 2024-06-30 13F ONCOCYTE COM 68235C206 17,346 17,346 51 0.0000
2023-11-13 2023-09-30 13F ONCOCYTE COM 68235C107 0 -194,911 -100.00 0 -100.00
2023-08-11 2023-06-30 13F ONCOCYTE COM 68235C107 194,911 0 0.00 45 -36.23 0.0000
2023-05-15 2023-03-31 13F ONCOCYTE COM 68235C107 194,911 -13,888 -6.65 69 2.99 0.0000
2023-02-13 2022-12-31 13F ONCOCYTE COM 68235C107 208,799 0 0.00 67 -55.92 0.0000
2022-11-14 2022-09-30 13F ONCOCYTE COM 68235C107 208,799 0 0.00 152 -19.15 0.0000
2022-08-12 2022-06-30 13F ONCOCYTE COM 68235C107 208,799 -343,110 -62.17 188 -77.13 0.0000
2022-05-13 2022-03-31 13F ONCOCYTE COM 68235C107 551,909 -30,633 -5.26 822 -34.97 0.0001
2022-02-08 2021-12-31 13F ONCOCYTE COM 68235C107 582,542 -12,387 -2.08 1,264 -40.32 0.0002
2021-11-15 2021-09-30 13F ONCOCYTE COM 68235C107 594,929 -217,967 -26.81 2,118 -54.62 0.0004
2021-08-13 2021-06-30 13F ONCOCYTE COM 68235C107 812,896 70,534 9.50 4,667 21.13 0.0008
2021-05-12 2021-03-31 13F ONCOCYTE COM 68235C107 742,362 63,742 9.39 3,853 137.55 0.0007
2021-02-11 2020-12-31 13F ONCOCYTE COM 68235C107 678,620 12,751 1.91 1,622 75.16 0.0003
2020-11-16 2020-09-30 13F ONCOCYTE COM 68235C107 665,869 171,837 34.78 926 -1.91 0.0002
2020-08-14 2020-06-30 13F ONCOCYTE COM 68235C107 494,032 199,062 67.49 944 30.57 0.0002
2020-05-14 2020-03-31 13F ONCOCYTE COM 68235C107 294,970 41,916 16.56 723 27.07 0.0002
2020-02-14 2019-12-31 13F ONCOCYTE COM 68235C107 253,054 3,369 1.35 569 8.59 0.0001
2019-11-13 2019-09-30 13F ONCOCYTE COM 68235C107 249,685 175,712 237.54 524 184.78 0.0001
2019-08-13 2019-06-30 13F ONCOCYTE COM 68235C107 73,973 18,100 32.39 184 -16.36 0.0000
2019-05-13 2019-03-31 13F ONCOCYTE COM 68235C107 55,873 40,996 275.57 220 1,000.00 0.0001
2019-02-12 2018-12-31 13F ONCOCYTE COM 68235C107 14,877 0 0.00 20 -45.95 0.0000
2018-11-14 2018-09-30 13F ONCOCYTE COM 68235C107 14,877 4,680 45.90 37 42.31 0.0000
2018-09-18 2018-06-30 13F/A-1 ONCOCYTE COM 68235C107 10,197 -33,867 -76.86 26 -71.74 0.0000
2018-08-14 2018-06-30 13F ONCOCYTE COM 68235C107 10,197 -33,867 26
2018-05-09 2018-03-31 13F ONCOCYTE COM 68235C107 44,064 16 0.04 92 -55.12 0.0000
2018-02-14 2017-12-31 13F ONCOCYTE COM 68235C107 44,048 128 0.29 205 -38.07 0.0001
2017-11-13 2017-09-30 13F ONCOCYTE COM 68235C107 43,920 3,188 7.83 331 56.87 0.0001
2017-08-11 2017-06-30 13F ONCOCYTE COM 68235C107 40,732 11,481 39.25 211 56.30 0.0001
2016-08-19 2016-03-31 13F/A-1 ONCOCYTE COM 68235C107 29,251 29,251 135 0.0000
2016-05-13 2016-03-31 13F ONCOCYTE COM 68235C107 29,251 29,251 135
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.